I
Ishani Dasgupta
Researcher at University of Massachusetts Medical School
Publications - 12
Citations - 411
Ishani Dasgupta is an academic researcher from University of Massachusetts Medical School. The author has contributed to research in topics: Hippo signaling pathway & Mechanotransduction. The author has an hindex of 5, co-authored 10 publications receiving 211 citations. Previous affiliations of Ishani Dasgupta include Indian Institute of Science.
Papers
More filters
Journal ArticleDOI
Control of cellular responses to mechanical cues through YAP/TAZ regulation.
Ishani Dasgupta,Dannel McCollum +1 more
TL;DR: This review will focus on how mechanical perturbations are sensed through changes in the actin cytoskeleton and mechanosensors at focal adhesions, adherens junctions, and the nuclear envelope to regulate YAP/TAZ.
Journal ArticleDOI
Recent Advances in miRNA Delivery Systems
TL;DR: In this paper, the strengths and weaknesses of current state-of-the-art viral and non-viral miRNA delivery systems and how these tools can be exploited to improve the outcomes of miRNA-based therapeutics.
Journal ArticleDOI
TRIP6 inhibits Hippo signaling in response to tension at adherens junctions.
Shubham Dutta,Sebastian Mana-Capelli,Murugan Paramasivam,Ishani Dasgupta,Heather A. Cirka,Kris Billiar,Dannel McCollum +6 more
TL;DR: It is shown that the LIM domain protein TRIP6 acts as part of a mechanotransduction pathway at adherens junctions to promote YAP activity by inhibiting the LATS1/2 kinases.
Journal ArticleDOI
Multifaceted roles of curcumin: two sides of a coin!
TL;DR: This is a consolidated review which aims to compare and contrast diverse aspects of curcumin in variety of diseases and shows its ability to act differentially as an anti-oxidant or pro-oxids akin to that of a double-edged sword/friend turning foe.
Journal ArticleDOI
CRISPR/Cas-Dependent and Nuclease-Free In Vivo Therapeutic Gene Editing
TL;DR: An overview of the CRISPR/Cas-mediated in vivo genome therapy applications and explore their prospective clinical translatability to treat human monogenic disorders is provided in this article.